S&P Futures
5,912.25 +6.25 (+0.11%) Dow Futures
43,569.00 +51.00 (+0.12%) Nasdaq Futures
20,511.50 +28.00 (+0.14%) Russell 2000 Futures
2,296.30 +5.10 (+0.22%) Crude Oil
69.32 +0.10 (+0.14%) Gold
2,742.50 +12.50 (+0.46%)
Nanobiotix S.A. (NANO.PA)
- GlobeNewswire
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Paris, France, October 11, 2024Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1
- GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune system before checkpoint therapySeveral clinical milestones expected over the next 12-18 months including updated data in pancreatic, and head and neck cancer, and initial data in esophageal and lung cancer€66.3 million in cash and cash equivalents as of June 30, 2024, with a cash runway extended i
